NEW YORK (GenomeWeb News) – Molecular diagnostics firm QuantuMDx and its university partners will use funding from the UK's Biomedical Catalyst program to develop and integrate the company's lab-on-a-chip technology into a device for rapidly diagnosing and staging cancers.

The company said on Sunday that it and its partners at the University of Newcastle and the University of Sheffield will use the £1.4 million ($2.2 million) in new funding to support development of a low-cost, sample-to-result benchtop device through an effort called the Q-Cancer project.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
01
Sponsored by
Horizon Discovery

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.